| scholarly article | Q13442814 |
| P2093 | author name string | Erin G Reid | |
| P2860 | cites work | Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy | Q24814325 |
| EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors | Q33261811 | ||
| Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034 | Q33561185 | ||
| Update on HHV-8-Associated Malignancies | Q33814153 | ||
| VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA | Q33971399 | ||
| Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma | Q34059058 | ||
| Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid | Q34187225 | ||
| Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model | Q34526773 | ||
| Trends in cancer risk among people with AIDS in the United States 1980-2002. | Q34569368 | ||
| Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma | Q35067397 | ||
| NF-kappaB inhibits gammaherpesvirus lytic replication | Q35155154 | ||
| Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors | Q37259751 | ||
| HIV-associated lymphomas and gamma-herpesviruses. | Q37310043 | ||
| Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection. | Q39618066 | ||
| Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus. | Q40363267 | ||
| Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma | Q42727447 | ||
| Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone | Q42914703 | ||
| A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma | Q44033069 | ||
| Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints | Q44203789 | ||
| The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells | Q45232203 | ||
| Virus-associated tumor imaging by induction of viral gene expression | Q45406615 | ||
| Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas | Q45422271 | ||
| Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998. | Q45722520 | ||
| Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin | Q46113172 | ||
| AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib | Q46120578 | ||
| A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab | Q46317413 | ||
| ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents | Q46343726 | ||
| Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma | Q46701461 | ||
| Distinct expression of Kaposi's sarcoma-associated herpesvirus-encoded proteins in Kaposi's sarcoma and multicentric Castleman's disease | Q61776908 | ||
| P433 | issue | 5 | |
| P921 | main subject | Epstein–Barr virus | Q6900 |
| oncolytic virus | Q1560099 | ||
| P304 | page(s) | 482-487 | |
| P577 | publication date | 2011-09-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Current Opinion in Oncology | Q1909046 |
| P1476 | title | Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies | |
| P478 | volume | 23 |
| Q64060829 | Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma |
| Q34045104 | Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects |
| Q38194845 | Diagnosis and management of lymphomas and other cancers in HIV-infected patients |
| Q42272334 | Epstein-Barr Virus and Posttransplant Lymphoproliferative Disorder in Solid Organ Transplantation |
| Q42222507 | In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications. |
| Q38271135 | KSHV targeted therapy: an update on inhibitors of viral lytic replication |
| Q40067410 | Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma. |
| Q38144129 | Review of latent and lytic phase biomarkers in Kaposi's sarcoma |
| Q64051817 | Silver nanoparticles selectively induce human oncogenic γ-herpesvirus-related cancer cell death through reactivating viral lytic replication |
| Q39181482 | The Oncolytic Effect of Respiratory Syncytial Virus (RSV) in Human Skin Cancer Cell Line, A431. |
Search more.